Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900747 | 0.84 | MCL1 (0.50) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3721647 | 0.82 | LMNA (0.53) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2142119 | 0.81 | TDP1 (0.55) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31094911 | 0.79 | MAPT (0.41) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5638960 | 0.79 | MAPT (0.41) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4107037 | 0.79 | SMN1; SMN2 (0.66) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL19758134 | 0.78 | SMN1; SMN2 (0.54) | LMNAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12474305 | 0.78 | ALDH1A1 (0.42) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL12180428 | 0.78 | MEN1 (0.44) | LMNAGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL25411980 | 0.77 | LMNA (0.43) | LMNAGAAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621922-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041858-A1 | A PROCESS FOR THE SYNTHESIS OF THIO-TRIAZOLO-GROUP CONTAINING COMPOUNDS | BASF SE (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-7893085-B2 | 3-(4-Bromo-2-fluoro-phenylamino)-thieno[3,2-c]pyridine-2-carboxylic acid (2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-amide; mitogen activated protein extracellular kinase kinase (MEK) inhibitor; antiproliferative, antiinflammatory agent | GENENTECH, INC (US) | 2011-02-22 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | LMNA 2872/4885GAA 1805/4885MAPT 4361/4885 |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | LMNA 1746/4885GAA 2671/4885MAPT 4374/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | LMNA 3058/4885GAA 3106/4885MAPT 4315/4885 |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | LMNA 1771/4885GAA 3502/4885MAPT 3153/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | LMNA 893/4885GAA 2351/4885MAPT 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.